Answer
Myocardial infarction and cerebrovascular events have been uncommonly reported in clinical studies with pemetrexed, usually combined with another cytotoxic agent, with most affected patients having pre-existing cardiovascular risk factors.
Sources for this answer
- Pemetrexed 25 mg/ml concentrate for solution for infusionGenus Pharmaceuticals · emc · SmPC §4.4 Special warnings and precautions for use · Version 2Document updated
Sources checked